Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,728.50
Bid: 1,727.00
Ask: 1,728.00
Change: 23.50 (1.38%)
Spread: 1.00 (0.058%)
Open: 1,705.00
High: 1,729.50
Low: 1,695.50
Prev. Close: 1,705.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-UK bluechips give up gains as sterling strengthens

Mon, 09th Sep 2019 09:52

* FTSE 100 down 0.6%, FTSE 250 down 0.1%

* Multinationals drop as pound gains

* ABF falls after weak trading update

* Shopping centre operator Intu jumps on deal report
(Adds company news items, updates share moves)

By Muvija M and Indranil Sarkar

Sept 9 (Reuters) - London's FTSE 100 fell on Monday as the
pound ploughed ahead after unexpectedly robust economic data and
as no-deal Brexit worries tempered, leaving
internationally-focussed stocks in the dumps.

The blue-chip index lost 0.6%, shedding earlier
gains and lagging its European peers, due to steep falls in
pharmaceutical shares AstraZeneca, GlaxoSmithKline
, and consumer goods giant Unilever.

The FTSE 250 index dipped 0.1%, though losses were
limited thanks to a 10.4% surge in Intu Properties
after the Times reported that private equity firm Orion Capital
Managers was looking to buy the shopping centre operator.

Sterling scaled a six-week high as fears of a recession were
kept in check after data showed Britain's economy picked up more
than expected in July despite Brexit uncertainty.

However, the local currency handed back some of those gains
after news that John Bercow, Speaker in Britain's House of
Commons, would be standing down from the role.

Over three years after Britain voted to leave the European
Union, matters have only gotten more complicated as the process
plays out.

In the latest twist, parliament passed a bill demanding that
Prime Minister Boris Johnson delay Brexit unless he strikes a
new deal, while his office insisted that Brexit would happen on
Oct. 31, "no ifs and buts".

A NO DEAL OR A NEW REFERENDUM

"An unsettled UK political and economic landscape could be
with us for some time," BlackRock analysts wrote in their weekly
note.

"Six months ago, a negotiated deal looked most likely; now,
the then-extreme outcomes – no-deal or a new referendum – look
to have become more plausible."

Helping contain losses on the main bourse were oil majors
Shell and BP, both of which eked out near 1%
gains on hopes that Saudi Arabia's new energy minister will
continue to support output cuts.

Elsewhere, Wall Street indexes gained on growing hopes that
central banks will step in with stimulus plans after a data
showed an unexpected fall in China's exports last month, while
another one pointed to a slowdown in Japan's economy in the
second quarter.

The weakness reflected an impact from the prolonged
Sino-U.S. trade war to global economic growth.

The dispute saw a sharp escalation last month when the
United States announced higher tariffs on Chinese goods. That
had dragged the FTSE 100 to its biggest monthly fall so far this
year that month.

On Monday, the index saw some news-related falls, with
Associated British Foods losing 2.1% after poor outlook
for its Primark fashion chain and British Airways owner IAG
dropping 1.5% as it cancelled nearly all its flights
due to strikes.
(Reporting by Indranil Sarkar in Bengaluru; editing by Arun
Koyyur and Toby Chopra)

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.